Compositions and methods for treating or preventing pain or other disorders

2-6. (canceled)

8-16. (canceled)

(canceled)

A method for treating or preventing pain in a patient, comprising administering to the patient at least one N-acylethanolamine (NAE) in combination with at least one cannabinoid, wherein the at least one cannabinoid is administered separately, sequentially or simultaneously to the at least one N-acylethanolamine (NAE)

• wherein the at least one N-acylethanolamine (NAE) is N-Palmitoylethanolamide (PEA) or an analog or derivative thereof;
• and
• wherein the at least one cannabinoid is one or more of Cannabidiol (CBD), Cannabigerol (CBG), Cannabidiolic Acid (CBDA) and Tetrahydrocannabinol (THC).

A method for preventing or treating pain-related symptoms in a patient, comprising administering to the patient at least one N-acylethanolamine (NAE) in combination with at least one cannabinoid, wherein the at least one of a cannabinoid is administered separately, sequentially or simultaneously to the at least one N-acylethanolamine (NAE)

• wherein the at least one N-acylethanolamine (NAE) is N-Palmitoylethanolamide (PEA) or an analog or derivative thereof;
• and
• wherein the at least one cannabinoid is one or more of Cannabidiol (CBD), Cannabigerol (CBG), Cannabidiolic Acid (CBDA) and Tetrahydrocannabinol (THC).

36-49. (canceled)

53-103. (canceled)

106-107. (canceled)

A method of inhibiting production of prostaglandins in a subject, comprising administering to the subject at least one N-acylethanolamine (NAE) in combination with at least one cannabinoid, wherein the at least one cannabinoid is administered separately, sequentially or simultaneously to the at least one N-acylethanolamine

• wherein the at least one N-acylethanolamine (NAE) is N-Palmitoylethanolamide (PEA) or an analog or derivative thereof;
• wherein the at least one cannabinoid is one or more of Cannabidiol (CBD), Cannabigerol (CBG), Cannabidiolic Acid (CBDA) and Tetrahydrocannabinol (THC);
• and wherein the composition if formulated for use for treatment or prevention of pain and/or pain-related symptoms in a subject.

109-115. (canceled)